Home - Translational Lung Cancer Research

New Impact Factor for Translational Lung Cancer Research: 4

We are pleased to announce that the Translational Lung Cancer Research (TLCR) has attained its latest impact factor update for the 2023 citation year: 4.

Translational Lung Cancer Research 2023 CiteScore Released: 7.2

We are pleased to announce that the Translational Lung Cancer Research (TLCR) has received its 2023 CiteScore: 7.2, ranking 92 out of 404 journals in the Oncology category.

Furthermore, we are delighted to highlight the remarkable achievements made by all AME journals in the CiteScore ranking.

Interviews with Outstanding Authors (2024)

In 2024, many authors make outstanding contributions to our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors, with a brief interview of their thoughts and insights as authors. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Reviewer of the Month (2024)

In 2024, TLCR reviewers continue to make outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

TLCR Annual Report 2023

Welcome to the 2023 annual report for Translational Lung Cancer Research. In 2023, the TLCR has continued its mission to increase the quality and impact of the journal, and to provide readers with a novel, well-organized, informative, enlightening and educational journal.

We would like to sincerely thank our Editorial Board Members, Guest editors, Reviewers, Authors, Readers for all your supports and contributions to TLCR in 2023, and we look forward to continuing our work with you in the new year.

‹ ›

Vol 13, No 8 (August, 2024)

Articles in Press

Past Issues

About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: [email protected]
Copyright related contact:
Email: [email protected]
Commercial Sales contact (Reprints, advertising, etc.):
Email: [email protected]

Editorial

The (un)lucky seven—how can we mitigate risk factors for postoperative pneumonia after lung resections?

Koen C. H. A. Verkoulen, Iris E. W. G. Laven, Jean H. T. Daemen, Juliette H. R. J. Degens, Lizza E. L. Hendriks, Karel W. E. Hulsewé, Yvonne L. J. Vissers, Erik R. de Loos

PDF Pages: 1763-1767 Full Text (47) Peer Review File COI Form Open Access

Original Article

Redefining YAP1 in small cell lung cancer: shifting from a dominant subtype marker to a favorable prognostic indicator

Se-Il Go, Jung Wook Yang, Eun Jeong Jeong, Woo Je Lee, Sungwoo Park, Dae Hyun Song, Gyeong-Won Lee

PDF Pages: 1768-1779 Full Text (56) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Identifying genetically-supported drug repurposing targets for non-small cell lung cancer through mendelian randomization of the druggable genome

Yi Feng, Caichen Li, Bo Cheng, Ying Chen, Peiling Chen, Zixun Wang, Xiangyuan Zheng, Juan He, Feng Zhu, Wei Wang, Wenhua Liang

PDF Pages: 1780-1793 Full Text (111) Reporting Checklist Peer Review File COI Form Open Access

CT-based radiomic consensus clustering association with tumor biological behavior in clinical stage IA adenocarcinoma: a retrospective study

Xin Wen, Meng-Wen Liu, Bin Qiu, Yan-Mei Wang, Jiu-Ming Jiang, Xue Zhang, Xu Jiang, Lin Li, Meng Li, Li Zhang

PDF Pages: 1794-1806 Full Text (71) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Safety and efficacy of immunotherapy using a double-dose regimen in advanced non-small cell lung cancer (NSCLC): results of IDEE study

Clémence Pierre, Yannick Le Guen, Caroline Giordanengo, Thomas Goter, Hervé Léna, Clémence Niel, Gonzague De Chabot, Marie Tiercin, Gwenaelle Le Garff, François Zimmermann, Quentin Le Cornu, Charles Ricordel

PDF Pages: 1807-1815 Full Text (58) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

LungPath: artificial intelligence-driven histologic pattern recognition for improved diagnosis of early-stage invasive lung adenocarcinoma

Haoda Huang, Zeping Yan, Bingliang Li, Weixiang Lu, Ping He, Lei Fan, Xiaowei Wu, Hengrui Liang, Jianxing He

PDF Pages: 1816-1827 Full Text (52) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Radiogenomics models for predicting prognosis in locally advanced non-small cell lung cancer patients undergoing definitive chemoradiotherapy

Xiaoyu Song, Li Li, Qingxi Yu, Ning Liu, Shouhui Zhu, Shuanghu Yuan

PDF Pages: 1828-1840 Full Text (58) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

A nomogram predicting the risk of extrathoracic metastasis at initial diagnosis of T_≤3cmN₀ lung cancer

Tengyong Wang, Zihuai Wang, Jian Zhou, Hui Jie, Hu Liao, Jiandong Mei, Qiang Pu, Lunxu Liu

PDF Pages: 1841-1850 Full Text (37) Reporting Checklist Peer Review File COI Form Open Access

Effect of family history of cancer on postoperative survival in patients with non-small cell lung cancer

Jian Zhou, Quan Zheng, Yuchen Huang, Mengyuan Lyu, Tengyong Wang, Dongsheng Wu, Hu Liao

PDF Pages: 1851-1861 Full Text (52) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Evaluation of the novel International Association for the Study of Lung Cancer grading system in adenocarcinoma with spread through air space

Kuan Xu, Yilv Lv, Tangbing Chen, Yuchen Han, Hanqing Huang, Hong Yu, Bo Ye

PDF Pages: 1862-1876 Full Text (51) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Knowledge and beliefs about lung cancer screening among Black individuals at high risk: a qualitative approach

Abdi T. Gudina, Charles Kamen, Lindsey J. Mattick, Francisco Cartujano-Barrera, Michelle C. Janelsins, Deborah Ossip, M. Patricia Rivera, Kevin Fiscella, Ana-Paula Cupertino

PDF Pages: 1877-1887 Full Text (56) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Prognostic and predictive significance of soluble programmed death ligand 1 in bronchoalveolar lavage fluid in stage IV non-small cell lung cancer

So-yun Kim, Dongil Park, Pureum Sun, Nayoung Kim, Dahye Lee, Duk Ki Kim, Song-I Lee, Jeong Eun Lee, Chaeuk Chung, Da Hyun Kang

PDF Pages: 1888-1906 Full Text (65) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Assessing the transportability of radiomic models for lung cancer diagnosis: commercial vs. open-source feature extractors

David Xiao, Michael N. Kammer, Heidi Chen, Palina Woodhouse, Kim L. Sandler, Anna E. Baron, David O. Wilson, Ehab Billatos, Jiantao Pu, Fabien Maldonado, Stephen A. Deppen, Eric L. Grogan

PDF Pages: 1907-1917 Full Text (71) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Emphysema and lung cancer risk

Agata Durawa, Katarzyna Dziadziuszko, Małgorzata Jelitto, Michał Gąsiorowski, Mariusz Kaszubowski, Edyta Szurowska, Witold Rzyman

PDF Pages: 1918-1928 Full Text (51) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study

Nobutaka Kataoka, Yuki Katayama, Tadaaki Yamada, Kenji Morimoto, Takayuki Takeda, Asuka Okada, Shinsuke Shiotsu, Yusuke Chihara, Osamu Hiranuma, Takahiro Yamada, Takahiro Ota, Taishi Harada, Isao Hasegawa, Naoya Nishioka, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama

PDF Pages: 1929-1937 Full Text (55) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Clinical features and prognostic biomarkers in patients with SMARCA4-mutated non-small cell lung cancer

Jinyu Long, Ying Chen, Xingguang Luo, Ruiying Rao, Chenxi Wang, Yuxin Guo, Jinhe Xu, Ping Lin, Yingfang Song, Lijuan Qu, Qinghong Liu, Jun Lu, Chengzhi Zhou, Zhengbo Song, Xiandong Lin, Hiroyuki Adachi, Jacek Jassem, Masatsugu Hamaji, Zongyang Yu

PDF Pages: 1938-1949 Full Text (38) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Efficacy and prognostic factors of stereotactic body radiotherapy combined with immunotherapy for pulmonary oligometastases: a preliminary retrospective cohort study

Mei-Na Piao, Jing Xie, Min-Min Jin, Xiao-Ting Ma, Zheng Dou, Jian-Ping Wang, Jin-Li Li

PDF Pages: 1950-1963 Full Text (49) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Effective induction immunotherapy minimizes surgical invasiveness for locally advanced lung cancer

Feichao Bao, Jiaming Wang, Chen Shen, Fenghao Yu, Marko Jakopović, Xiuxiu Hao, Yang Chen, Yiyang Wang, Zhitao Gu, Wentao Fang

PDF Pages: 1964-1974 Full Text (37) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Prognostic role of dynamic changes in inflammatory indicators in patients with non-small cell lung cancer treated with immune checkpoint inhibitors—a retrospective cohort study

Liang Guo, Juanjuan Li, Jing Wang, Xinru Chen, Chenlei Cai, Fei Zhou, Anwen Xiong

PDF Pages: 1975-1987 Full Text (50) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Single-center clinical experience of extended sleeve lobectomy (ESL) versus standard sleeve lobectomy (SL)

Haoyou Wang, Wei Wang, Peng Zu, Gregor J. Kocher, Mara B. Antonoff, Alberto Lopez-Pastorini, Chenlei Zhang, Wei Chen, Hongxu Liu

PDF Pages: 1988-1999 Full Text (52) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Enhanced tumor targeting and penetration of fluorophores via iRGD peptide conjugation: a strategy for the precision targeting of lung cancer

Yunlong Li, Chenmei Li, Jiamin Li, Dong Han, Gang Xu, Daolong Zhu, Huiming Cai, Yiqing Wang, Dong Wang

PDF Pages: 2000-2014 Full Text (53) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Efficacy of ALK inhibitors in Asian patients with ALK inhibitor-naïve advanced ALK-positive non-small cell lung cancer: a systematic review and network meta-analysis

Xuchang Li, Yangchen Xia, Chengyan Wang, Shanshan Huang, Qian Chu

PDF Pages: 2015-2022 Full Text (84) Reporting Checklist Peer Review File COI Form Open Access

Neutrophil estimation and prognosis analysis based on existing lung squamous cell carcinoma datasets: the development and validation of a prognosis prediction model

Youyu Wang, Dongfang Li, Qiang Li, Alina Basnet, Jimmy T. Efird, Nobuhiko Seki

PDF Pages: 2023-2037 Full Text (41) Reporting Checklist Peer Review File COI Form Open Access

Case Report

Successful carinal reconstruction with right main bronchial flap rotational embedded augmentation: a case report

Lin Xu, Wenjie Xia, Rong Yin, Ninglei Qiu

PDF Pages: 2038-2042 Full Text (51) Reporting Checklist Peer Review File COI Form Open Access

Immune-related osteoblastic bone alterations mimicking bone metastasis in a small-cell lung cancer patient treated with durvalumab: a case report

Dan Pu, Hong-E Zhang, Lu Li

PDF Pages: 2043-2049 Full Text (50) Reporting Checklist Peer Review File COI Form Open Access

Review Article

Oncogene-addicted solid tumors and microbiome—lung cancer as a main character: a narrative review

Mora Guardamagna, May-Lucie Meyer, Miguel Ángel Berciano-Guerrero, Andres Mesas-Ruiz, Manuel Cobo-Dols, Elisabeth Perez-Ruiz, Alexandra Cantero Gonzalez, Rocío Lavado-Valenzuela, Isabel Barragán, Javier Oliver, Alicia Garrido-Aranda, Martina Alvarez, Antonio Rueda-Dominguez, María Isabel Queipo-Ortuño, Emilio Alba Conejo, Jose Carlos Benitez

PDF Pages: 2050-2066 Full Text (43) Reporting Checklist Peer Review File COI Form Open Access

Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review

Bin Liu, Ziyu Wang, Meng Gu, Jinghui Wang, Jinjing Tan

PDF Pages: 2067-2081 Full Text (72) Reporting Checklist Peer Review File COI Form Open Access

Editorial Commentary

REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer?

Julie Dardare, Andréa Witz, Alexandre Harlé

PDF Pages: 2082-2086 Full Text (40) Peer Review File COI Form Open Access

Are PD-1T TILs merely an expensive and unuseful whim as biomarker?

Esther Garcia-Lorenzo, Victor Moreno

PDF Pages: 2087-2090 Full Text (47) Peer Review File COI Form Open Access

Can a dysfunctional T-cell gene signature predict nonresponse to PD-1 blockade in non-small cell lung cancer?

Hirokazu Taniguchi, Kazuto Ashizawa, Hiroshi Mukae

PDF Pages: 2091-2094 Full Text (29) Peer Review File COI Form Open Access

Clinical insights: five-year follow-up of KEYNOTE-189 trial outcomes and more

Bobby Se, Athar Eysa, Nagla Karim

PDF Pages: 2095-2097 Full Text (36) Peer Review File COI Form Open Access

Breaking barriers: patient-derived xenograft (PDX) models in lung cancer drug development—are we close to the finish line?

Nagla Abdel Karim, Mohamed Zaza, Janakiraman Subramanian

PDF Pages: 2098-2102 Full Text (35) Peer Review File COI Form Open Access

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors

Francesco Facchinetti, Marcello Tiseo, Massimo Di Maio, Paolo Graziano, Emilio Bria, Giulio Rossi, Silvia Novello

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps

Editorial

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M

Daniel B. Costa, Susumu S. Kobayashi

Review Articles

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?

Yoshihisa Kobayashi, Tetsuya Mitsudomi

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach

Javier de Castro Carpeño, Cristóbal Belda-Iniesta

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Non-small cell lung cancer: current treatment and future advances

Cecilia Zappa, Shaker A. Mousa

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer

Po Yee Yip

Lung cancer molecular epidemiology in China: recent trends

Caicun Zhou

The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention

Joanna Domagala-Kulawik

Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements

Cristina Teixidó, Niki Karachaliou, Vicente Peg, Ana Gimenez-Capitan, Rafael Rosell

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it

Christian Rolfo, Francesco Passiglia, Marta Castiglia, Luis E. Raez, Paul Germonpre, Ignacio Gil-Bazo, Karen Zwaenepoel, Annemieke De Wilde, Giuseppe Bronte, Antonio Russo, Jan P. Van Meerbeeck, Paul Van Schil, Patrick Pauwels

Highlighted Reports in European Lung Cancer Conference

Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines

Paul De Leyn, Christophe Dooms, Jaroslaw Kuzdzal, Didier Lardinois, Bernward Passlick, Ramon Rami-Porta, Akif Turna, Paul Van Schil, Frederico Venuta, David Waller, Walter Weder, Marcin Zielinski

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer

Paola Bordi, Marzia Del Re, Romano Danesi, Marcello Tiseo

Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies

Charles B. Simone II, Stuart H. Burri, John H. Heinzerling

Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)

Richard D. Hall, Tri M. Le, Daniel E. Haggstrom, Ryan D. Gentzler

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis

Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song

BRAF mutations in non-small cell lung cancer

Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper

The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer

Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper

Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice

Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer

Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song

Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer

Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R. Bowen

The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants

Randa A. El-Zein, Carol J. Etzel, Reginald F. Munden

The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices

Abdulhamid Chaikh, Jacques Balosso

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement

Hyojin Kim, Jin-Haeng Chung

Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer

Haoran Zhai, Wenzhao Zhong, Xuening Yang, Yi-Long Wu

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Clinical trials for lung cancer in China

Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Prognostic markers in lung cancer: is it ready for prime time?

Chang-Qi Zhu, Ming-Sound Tsao

Potential biomarkers for lung cancer screening

Gabriella Sozzi, Mattia Boeri

Particle therapy in non-small cell lung cancer

Zhongxing Liao, Charles B. Simone II

Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions

Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai

Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer

Neil K. Taunk, Andreas Rimner, Melissa Culligan, Joseph S. Friedberg, Julie Brahmer, Jamie Chaft

Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors

Suchit H. Patel, Andreas Rimner, Roger B. Cohen

Intraoperative near-infrared imaging of mesothelioma

Gregory Thomas Kennedy, Andrew Newton, Jarrod Predina, Sunil Singhal

BAP1, a tumor suppressor gene driving malignant mesothelioma

Mitchell Cheung, Joseph R. Testa

Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation

Jonathan E. Schoenhals, Steven N. Seyedin, Clark Anderson, Eric D. Brooks, Yun R. Li, Ahmed I. Younes, Sharareh Niknam, Ailin Li, Hampartsoum B. Barsoumian, Maria Angelica Cortez, James W. Welsh

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Zhongjian Chen, Giovanni Gaudino, Harvey I. Pass, Michele Carbone, Haining Yang

Immunotherapy for malignant pleural mesothelioma: current status and future directions

Jordan Dozier, Hua Zheng, Prasad S. Adusumilli

Biology and clinical significance of circulating tumor cell subpopulations in lung cancer

Linda O’Flaherty, Harriet Wikman, Klaus Pantel

Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?

Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Cyril Catelain, Françoise Farace

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Sumitra Mohan, Francesca Chemi, Ged Brady

Biophysical technologies for understanding circulating tumor cell biology and metastasis

Derrick W. Su, Jorge Nieva

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Marianna Gallo, Antonella De Luca, Monica Rosaria Maiello, Amelia D’Alessio, Claudia Esposito, Nicoletta Chicchinelli, Laura Forgione, Maria Carmela Piccirillo, Gaetano Rocco, Alessandro Morabito, Gerardo Botti, Nicola Normanno

Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer

Salma K. Jabbour, Abigail T. Berman, Charles B. Simone II

Editorial

An alternative way to initiate Notch1 signaling in non-small cell lung cancer

Yi-Lin Yang, David Jablons, Liang You

Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Fernando C. Santini, Siddharth Kunte, Alexander Drilon

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis

Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

China Lung Cancer Research Highlight

Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: a flavor of Dll4/Notch1 pleiotropy in tumor cell biology

Maria Felice Brizzi, Paola Defilippi

Editorials

Dulanermin in cancer therapy: Still much to do

Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data

Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner

Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung

Pedro Mendez, Jose Luis Ramirez

Role of HGF/MET axis in resistance of lung cancer to contemporary management

Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr

Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review

Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Ceritinib

Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer

Daniel B. Costa

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack

Lorenza Landi, Federico Cappuzzo

Nivolumab

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer

Arun Rajan, James L. Gulley

Brief Report

The role of Imaging and Radiation Oncology Core for precision medicine era of clinical trial

Ying Xiao, Mark Rosen

Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer

Biology of invasive mucinous adenocarcinoma of the lung

Yoon Jin Cha, Hyo Sup Shim

Immunohistochemistry for predictive biomarkers in non-small cell lung cancer

Mari Mino- Kenudson

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.

Currently no content available!

Journal Highlight more

Translational Lung Cancer Research is an international, peer-reviewed, open-access journal indexed by Science Citation Index Expanded (SCIE) and PubMed/PubMed Central, focusing on cutting-edge development on the transition from preclinical to clinical research, including but not limited to multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases.